AbbVie's Zumilokibart Shows Positive Phase 2 Results in Atopic Dermatitis
ABBV sits 38% above its 52-week low of $190.75.
Summary
AbbVie reported positive phase 2 data for Zumilokibart in atopic dermatitis. This is a new clinical milestone for a pipeline asset in a large dermatology market. The data could support advancement to phase 3 and expand AbbVie's immunology franchise beyond Skyrizi and Rinvoq. No specific efficacy numbers were disclosed in the headline, but the positive readout is a meaningful de-risking event for the program. Watch for detailed results at an upcoming medical meeting or regulatory update.
At the time of this announcement, ABBV was trading at $263.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $465.3B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.